StreetInsider.com News Articles

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 08:00:00 -0400

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, on Monday, September 14, 2026, in New York.

Mr. Ho and members of the IN8bio management team will host one-on-one meetings with investors throughout the conference.

H.C. Wainwright 28th Annual Global Investment Conference
Date: Monday, September 14,

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 08:00:00 -0400

Mr. Ho and members of the IN8bio management team will host one-on-one meetings with investors throughout the conference.

H.C. Wainwright 28th Annual Global Investment Conference
Date: Monday, September 14,

Form SCHEDULE 13G/A IN8BIO, INC. Filed by: LYTTON LAURENCE W

Thu, 13 Aug 2026 14:22:00 -0400

si-local-file:///var/storage/secattach/20260813/26919854.html

Form SCHEDULE 13G/A IN8BIO, INC. Filed by: LYTTON LAURENCE W

Thu, 13 Aug 2026 14:22:00 -0400

si-local-file:///var/storage/secattach/20260813/26919854.html

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 10 Aug 2026 16:01:00 -0400

NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase an aggregate of 4,000 shares of its common stock. The award was approved by the Compensation Committee of the Company’s Board of Directors and was granted pursuant to the Company’s 2026 Inducement Plan, with a grant date of August 3, 2026, as an

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 10 Aug 2026 16:01:00 -0400

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 10 Aug 2026 16:01:00 -0400

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 10 Aug 2026 16:01:00 -0400

Form S-8 IN8BIO, INC.

Fri, 07 Aug 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260807/26886918.html

Form S-8 IN8BIO, INC.

Fri, 07 Aug 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260807/26886918.html

IN8bio, Inc (INAB) Tops Q2 EPS by 9c

Thu, 06 Aug 2026 16:24:26 -0400

IN8bio, Inc (NASDAQ: INAB) reported Q2 EPS of ($0.25), $0.09 better than the analyst estimate of ($0.34).

For earnings history and earnings-related data on IN8bio, Inc (INAB) click here.

Form 10-Q IN8BIO, INC. For: Jun 30

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884081.html

Form 10-Q IN8BIO, INC. For: Jun 30

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884081.html

Form 8-K IN8BIO, INC. For: Aug 06

Thu, 06 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260806/26883644.html

Form 8-K IN8BIO, INC. For: Aug 06

Thu, 06 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260806/26883644.html

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights